Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service spinal cord & DRG stimulation cases in West Virginia: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (170 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 9 | 261 | 36% |
| 2020 | 3 | 180 | 41% |
| 2021 | 4 | 169 | 46% |
Permanent stimulator implants, counted by the generator; trial and permanent leads and revisions are fetched but not counted as cases. Professional codes (what the surgeon bills): CPT 63685.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in West Virginia; 1 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Radiofrequency ablation (facet, genicular, basivertebral) | 24 | 1,871−2.4%/yr | −2.4%/yr | 8.50.6× | 17% | 2,300 in 2030+3.5%/yr |
Spinal cord & DRG stimulation in every state, and its device makers · Every procedure market in West Virginia · Every state · Compare with Texas
| 2024 |
| 120 |
| 58% |
| 2025 est. | ≈ 140 | – |
| 2026 est. | ≈ 130 | – |
| 2022 | 3 | 185 | 50% |
| 2023 | 4 | 125 | 55% |
| 2024 | 1 | 120 | 58% |
| 2025 from claims | – | 135 109–159 | 59% |
| 2026 forecast | – | 132 104–166 | 60% |
| 2027 forecast | – | 130 97–172 | 61% |
| 2028 forecast | – | 128 91–176 | 62% |
| 2029 forecast | – | 125 85–180 | 63% |
| 2030 forecast | – | 123 81–183 | 64% |
In 2025, 100% hospital outpatient.
| 1,901−2%/yr |
| −2%/yr |
| 0.8 |
| 65% |
| 2,240 in 2030+2.8%/yr |
| North Carolina | 27 | 1,005−2%/yr | −2%/yr | 0.9 | 45% | 950 in 2030−0.9%/yr |
| Tennessee | 22 | 830+1.8%/yr | +1.8%/yr | 1.1 | 70% | 1,040 in 2030+3.9%/yr |
| Georgia | 17 | 798−4.7%/yr | −4.7%/yr | 0.8 | 69% | 850 in 2030+1.1%/yr |
| Oklahoma | 21 | 734−3%/yr | −3%/yr | 1.4 | 45% | 850 in 2030+2.5%/yr |
| South Carolina | 21 | 702−4.7%/yr | −4.7%/yr | 1.0 | 36% | 710 in 2030+0.1%/yr |
| Maryland | 13 | 599+6.8%/yr | +6.8%/yr | 0.7 | 87% | 820 in 2030+5.5%/yr |
| Virginia | 13 | 494−4.5%/yr | −4.5%/yr | 0.4 | 18% | 600 in 2030+3.3%/yr |
| Louisiana | 10 | 385−5.1%/yr | −5.1%/yr | 0.9 | 52% | 420 in 2030+1.4%/yr |
| Mississippi | 10 | 380−3%/yr | −3%/yr | 1.0 | 72% | 490 in 2030+4.5%/yr |
| Kentucky | 7 | 342−3.7%/yr | −3.7%/yr | 0.7 | 42% | 480 in 2030+5.7%/yr |
| Arkansas | 11 | 302−2.5%/yr | −2.5%/yr | 0.7 | 51% | 330 in 2030+1.3%/yr |
| Alabama | 4 | 201−12%/yr | −12%/yr | 0.4 | 35% | 180 in 2030−1.6%/yr |
| 3 |
| 158+6.2%/yr |
| +6.2%/yr |
| 0.70.5× |
| 27% |
| 100 in 2030−7%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Abbott leads with 52% of company spending on these surgeons in 2025, +7 pts on 2024.
In 2025, 9 companies reported engagement with West Virginia’s surgeons worth $282K in consulting, speaking, meals and travel tied to these products, about $282K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 63 clearances and approvals in the category, 4 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.